Watch CVSI. Know when insiders buy.
One email the day a filing lands. Free.
CVSI
CV Sciences, Inc.
0.02
+0.00 +0.00%
USD · close Sep 9
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
31
FLAG · insiders 61, shorts 0
Insiders, 90 days
+$115K
net buying · 10 buys, 0 sells
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $4.5MP/E —DIV YIELD —FCF YIELD -11.56%REV TTM $12.7M −14.9%NET INCOME −$2MNET DEBT $1M52W 0.02 – 0.09SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $3M | −17.5% | 48.6% | −$301K | −$775K | — | 0.00 | $20K | $7K | $13K | Aug 13 |
| Q1 2026 · Mar 31 | $3.2M | −11.4% | 48.9% | −$318K | −$643K | — | 0.00 | $101K | $3K | $98K | Aug 13 |
| Q4 2025 · Dec 31derived | $3.3M | −14.9% | 50.5% | −$75K | −$206K | — | -0.01 | −$354K | $9K | −$363K | Mar 26 |
| Q3 2025 · Sep 30 | $3.3M | −15.8% | 48.5% | −$275K | −$382K | — | 0.00 | −$259K | $11K | −$270K | Nov 13 |
| Q2 2025 · Jun 30 | $3.6M | −8.4% | 50.9% | −$131K | −$261K | — | 0.00 | $287K | $49K | $238K | Aug 13 |
| Q1 2025 · Mar 31 | $3.6M | −9.9% | 46.0% | $11K | −$109K | — | 0.00 | −$81K | $40K | −$121K | Aug 13 |
| Q4 2024 · Dec 31derived | $3.9M | +2.2% | 43.2% | −$646K | −$726K | — | 0.00 | −$164K | $18K | −$182K | Mar 26 |
| Q3 2024 · Sep 30 | $3.9M | −5.5% | 46.0% | −$341K | −$456K | — | 0.00 | −$122K | $0 | −$122K | Nov 13 |
| Q2 2024 · Jun 30 | $4M | — | 47.0% | −$583K | −$584K | — | 0.00 | −$57K | $0 | −$57K | Nov 13 |
| Q1 2024 · Mar 31 | $4M | — | 46.3% | −$620K | −$628K | — | 0.00 | −$518K | $0 | −$518K | Nov 13 |
| Q4 2023 · Dec 31derived | $3.8M | — | 45.8% | −$889K | −$869K | — | -0.01 | −$114K | — | — | Mar 27 |
| Q3 2023 · Sep 30 | $4.1M | — | 45.1% | −$437K | −$447K | — | 0.00 | −$19K | — | — | Nov 14 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $13.8M | 49.0% | −$470K | −$958K | -6.9% | -0.01 | −$407K | $109K | −$516K | — | — |
| FY2024 · to Dec 31 | $15.7M | 45.6% | −$2.2M | −$2.4M | -15.2% | -0.01 | −$861K | $18K | −$879K | — | — |
| FY2023 · to Dec 31 | $16M | 44.3% | $3.4M | $3.1M | 19.4% | 0.02 | $2.3M | $0 | $2.3M | — | — |
| FY2022 · to Dec 31 | $16.2M | 34.2% | −$6.8M | −$8.2M | -50.7% | -0.07 | −$1.9M | $0 | −$1.9M | — | — |
| FY2021 · to Dec 31 | $20M | 43.0% | −$18.4M | −$15.6M | -77.6% | -0.14 | −$7.5M | $35K | −$7.5M | — | — |
| FY2020 · to Dec 31 | $24.4M | 45.1% | −$22.6M | −$22.3M | -91.2% | -0.22 | −$7.3M | $1.1M | −$8.4M | — | — |
Every number comes from CV Sciences, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.